The utility of the gonadotrophin releasing hormone (GnRH) test in the diagnosis of polycystic ovary syndrome (PCOS)

Endokrynologia Polska

Volumn 62, Issue 2, 2011, Pages 120-128

  Lewandowski, Krzysztof C ^a,b   Cajdler Łuba, Agata ^b   Salata, Ireneusz ^a,b   Bieńkiewicz, Małgorzata ^a   Lewiński, Andrzej ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

CnRH test; Insulin resistance; Oligomenorrhoea; Polycystic ovary syndrome

Indexed keywords

ANDROSTENEDIONE; ESTRADIOL; FOLLITROPIN; GLUCOSE; GONADORELIN; INSULIN; LUTEINIZING HORMONE; PROGESTERONE; TESTOSTERONE;

ADULT; AMENORRHEA; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; FOLLITROPIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GONADORELIN TEST; HIRSUTISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OLIGOMENORRHEA; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; SENSITIVITY AND SPECIFICITY;

17-ALPHA-HYDROXYPROGESTERONE; ADULT; ANDROSTENEDIONE; BIOLOGICAL MARKERS; FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; GONADOTROPINS; HUMANS; INSULIN; LUTEINIZING HORMONE; MENSTRUAL CYCLE; OLIGOMENORRHEA; POLYCYSTIC OVARY SYNDROME; PREDICTIVE VALUE OF TESTS; TESTOSTERONE; YOUNG ADULT;

EID: 79957978743     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Azziz R, Woods KS, Reyna R et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745-2749. (Pubitemid 38766360)
2. Ehrmann DA, Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223-1236.
3. Conway GS, Honour JW, Jacobs HS. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin Endocrinol (Oxf) 1989; 30: 459-470. (Pubitemid 19110020)
4. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Human Reprod 2004; 19: 41-47.
5. Milewicz A, Silber D, Mielecki T. The origin of androgen synthesis in polycystic ovary syndrome. Obstet Gynecol 1983; 62: 601-614.
6. Taylor AE, McCourt B, Martin KA et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 2248-2256. (Pubitemid 27287593)
7. Blank SK, McCartney CR, Marshall JC. The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. Human Reprod Update 2006; 12: 351-361. (Pubitemid 43923410)
8. Rosenfield RL. Identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92: 787-796. (Pubitemid 46465641)
9. Barnes RB, Rosenfield RL, Burstein S et al. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med 1989; 320: 559-565. (Pubitemid 19070540)
10. Ehrmann DA, Rosenfield RL, Barnes RB et al. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 1992; 327: 157-162.
11. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocrine Rev 1995; 16: 322-353.
12. Karasek M, Pawlikowski M, Lewiński A. Hyperprolactinemia: causes, diagnosis, and treatment. Endokrynol Pol 2006; 57: 656-662.
13. Arnaldi G, Angeli A, Atkinson AB et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2003; 88: 5593-5602. (Pubitemid 38033020)
14. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419. (Pubitemid 15018832)
15. Belfiore F, Iannello S, Volpicelli G. Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels. Mol Genet Metab 1998; 63: 134-141. (Pubitemid 28453331)
16. Matsuda M, DeFronzo R. Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 1999; 9: 1462-1470.
17. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol. Metab 1961; 21: 1440-1447.
18. Balen AH, Laven JS, Tan SL et al. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003; 9: 505-514. (Pubitemid 38072143)
19. Rosenfield RL, Ehrmann DA, Barnes RB et al. Gonadotropin-releasing hormone agonist as a probe for the pathogenesis and diagnosis of ovarian hyperandrogenism. Ann N Y Acad Sci 1993; 687: 161-181.
20. Lawson MA, Jain S, Sun S et al. Evidence for insulin suppression of baseline luteininising hormone in women with polycystic ovarian syndrome and normal women. J Clin Endocrinol Metab 2008; 93: 2089-2096. (Pubitemid 351831520)
21. Ferris HA, Shupnik MA. Mechanisms for pulsatile regulation of the gonadotropin subunit genes by GnRH1. Biol Reprod 2006; 74: 993-998. (Pubitemid 47394279)
22. Marshall JC, Dalkin AC, Haisenleder DJ et al. Gonadotropin releasing hormone pulses: regulators of gonadotropin synthesis and ovolulatory cycles. Rec Prog Horm Res 1991; 47: 155-187.
23. Marshall JC, Eagleson CA. Neuroendocrine aspects of polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999; 28: 295-324. (Pubitemid 29242715)
24. Nippoldt TB, Reame NE, Kelch RP et al. The roles of estradiol and progesterone in decreasing luteinizing hormone pulse frequency in the luteal phase of the menstrual cycle. J Clin Endocrinol Metab 1989; 69: 67-76. (Pubitemid 19172428)
25. Romano GJ, Krust A, Pfaff DW. Expression and estrogen regulation of progesterone receptor mRNA in neurons of the mediobasal hypothalamus: an in situ hybridization study. Mol Endocrinol 1989; 3: 1295-1300. (Pubitemid 19210441)
26. Soules MR, Steiner RA, Clifton DK et al. Progesterone modulation of pulsatile luteinizing hormone secretion in normal women. J Clin Endocrinol Metab 1984; 58: 378-383. (Pubitemid 14184147)
27. Berga SL, Yen SS. Opioidergenic regulation of LH pulsatility in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1989; 30: 177-184. (Pubitemid 19063222)
28. Neal-Perry G, Lebesgue D, Lederman M et al. The excitatory peptide kisspeptin restores the luteinizing hormone surge and modulates amino acid neurotransmission in the medial preoptic area of middle-aged rats. Endocrinology 2009;150:3699-3708.
29. Kazer RR, Kessel B, Yen SS. LH pulse frequency in women with PCO. J Clin Endocrinol Metab. 1987; 65: 233-236.
30. Waldstreicher J, Santoro NF, Hall JE et al. Hyperfunction of the hypothalamic pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab 1988; 66: 165-172. (Pubitemid 18027747)
31. Carmen LP, Griffin-Korf ML, Aloi JA et al. Polycystic ovary syndrome: Evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 1998; 83: 582-590. (Pubitemid 28496543)
32. Blank SK, McCartney CR, Chhabra S et al. Modulation of gonadotropin-releasing hormone pulse generator sensitivity to progesterone inhibition in hyperandrogenic adolescent girls - implications for regulation of pubertal maturation. J Clin Endocrinol Metab 2009; 94: 2360-2366.
33. Apter D, Butzow T, Laughlin GA et al. Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovary syndrome. J Clin Endocrin Metab 1994; 79: 119-125. (Pubitemid 24221170)
34. Chabra S, McCartney CR, Yoo RY et al. Progesterone inhibition of the hypothalamic gonadotropin-releasing hormone pulse generator evidence for varied effects in hyperandrogenemic adolescent girls. J Clin Endocrin Metab 2005; 90: 2810-2815. (Pubitemid 40686328)
35. Taylor AE. Polycystic ovary syndrome. Endocrinol Metab Clin North Am 1998; 27: 877-902. (Pubitemid 28564062)
36. Stewart PM, Penn R, Holder R et al. The hypothalamo-pituitary-adrenal axis across the normal menstrual cycle and in polycystic ovary syndrome. Clin Endocrinol (Oxf) 1993; 38: 387-391. (Pubitemid 23105071)
37. Koskinen P, Penttila T, Anttila L et al. Optimal use of hormone determinations in the biochemical diagnosis of the polycystic ovary syndrome. Fertil Steril 1996; 65: 517-522. (Pubitemid 26069105)
38. Jasonni VM, Bullletti C, Naldi S et al. Treatment of hirsutism by an association of of oral cyproproterone acetate and transdermal 17-b-estradiol. Fertil Steril 1991; 55: 742-745.
39. Barth JH, Yasmin E, Balen AH. The diagnosis of polycystic ovary syndrome: the criteria are insufficiently robust for clinical research. Clin Endocrinol (Oxf) 2007; 67: 811-815.
40. Arroyo A, Laughlin GA, Morales AJ et al. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. J Clin Endocrin Metab 1997; 82: 3728-3733. (Pubitemid 27509362)
41. Morales AJ, Laughlin GA, Butzow T et al. Insulin, somatotropic and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 1996; 81: 2854-2864. (Pubitemid 26326301)
42. Dale PO, Tanbo T, Vaaler S et al. Body weight, hyperinsulinaemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations. Fertil Steril 1992; 58: 487-491.
43. Ke WX, Shan GQ, Hua SY. Different responses of insulin, C-peptide, and testosterone to an oral glucose tolerance test in two groups of women with polycystic ovarian syndrome. Acta Obstet Gynecol Scand 1996; 75: 166-169.
44. Banaszewska B, Spaczyński RZ, Pelesz M et al. Incidence of elevated LH/FSH ratio in polycystic ovary syndrome women with normo- and hyperinsulinaemia. Rocz Akad Med Bialymst 2003; 48: 131-134.
45. Patel K, Cofferr MS, Dahan MH et al. Relationship of GnRH-stimulated LH release to episodic LH secretion and baseline endocrine-metabolic measures in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004; 60: 67-74. (Pubitemid 38183500)
46. Balen AH, Conway GS, Kaltsas G et al. Polycystic ovary syndrome: The spectrum of the disorder in 1741 patients. Hum Reprod 1995; 10: 2705-2712.
47. Barth JH. What service does the laboratory provide? Endocrine Abstracts 2009; 19: S46.
48. Fears TR, Ziegler RG, Donaldson JL et al. Reproducibility studies and interlaboratory concordance for androgen assays in female plasma. Cancer Epidemiol Biomarkers Prev. 2000; 9: 403-412. (Pubitemid 30265784)
49. Boots LR, Potter S, Potter D et al. Measurement of total serum testosterone levels using commercially available kits: high degree of between-kit variability. Fertil Steril. 1998; 69: 286-292. (Pubitemid 28117108)
50. Vesper HW, Bhasin S, Wang C et al. Interlaboratory comparison study of serum total testosterone measurements performed by mass spectrometry methods. Steroids 2009; 74: 498-503.
51. Azziz Z, Carmina E, Dewailly D et al. Androgen Excess Society 2006 Positions Statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91: 4237-4245.
52. Pasquali R, Patton L, Pocognoli P et al. 17-Hydroxyprogesterone responses to gonadotropin-releasing hormone disclose phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92: 4208-4217. (Pubitemid 350074733)